一、停复牌 嘉事堂：股东光大实业筹划公司股权转让，股票停牌。 二、回购 片仔癀：控股股东九龙江集团拟3亿元-5亿元增持公司股份。创新药PZH2113胶囊Ⅰ期临床试验完成首 例受试者入组，国内外暂无相同适应症的同靶点药品获批上市。 三、并购重组 泰凌微：拟通过发行股份及支付现金方式收购磐启微100%股权。 四、经营 1、百通能源：拟通过全资子公司图达铝业与安哥拉共和国丹德港发展有限公司签订《投资意向协 议》，拟以自有及自筹资金约4亿美元对外投资，并设立全资公司百通图达（安哥拉）铝业有限公司。 2、普洛药业：与杭州德睿智药科技有限公司签订《战略合作框架协议》，开展CDMO项目的长期合 作。 3、诺德股份：拟对全资子公司青海电子2010年投资建设的二厂1.5万吨生产线设备实施更新改造，项目 总投资估算为人民币1.68亿元；改造完成后，生产范围将从原有设计规格为6-8微米及以上常规锂电铜 箔，拓展至具备4.5微米及以下高端锂电铜箔的量产能力。 五、业绩变动 1、国泰海通：2025年净利润为275.33亿元至280.06亿元，同比增加111%至115%。财富管理、机构与交 易等业务收入同比显著增长。 6、南亚新材：20 ...

Group 1 - Prolo Pharma announced a strategic cooperation framework agreement with Hangzhou Derui Zhiyao Technology Co., Ltd. to engage in long-term collaboration on CDMO projects [1] - The signed framework agreement is non-binding and does not involve substantial transactions, nor does it constitute a related party transaction or a major asset restructuring as defined by the regulations [1] - The agreement does not require approval from the company's board of directors or shareholders [1]

证券代码：000739 证券简称：普洛药业 公告编号：2026-05 普洛药业股份有限公司 关于签署战略合作框架协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 1.本次公司与合作方签署的《战略合作框架协议》，本着平等互利、优 势互补的原则，经友好协商，就创新药研发与外包定制生产项目（以下简称 "CDMO项目"）的合作关系达成共识。具体项目合作事宜将由双方另行签署 具体协议。 2.本次签署的《战略合作框架协议》对公司本年度经营业绩不会构成 重大影响，对公司未来年度经营业绩的影响将视公司与合作方后续签订的 具体项目协议以及实施情况而确定。 3.公司不存在最近三年披露的框架协议无进展或进展未达预期的情况。 一、战略框架协议签署概况 普洛药业股份有限公司(以下简称"公司"或"乙方")与杭州德睿智 药科技有限公司（以下简称"德睿智药"或"甲方"）本着平等互利、优 势互补的原则，于近日签订了《战略合作框架协议》，甲乙双方结成战略 合作伙伴，开展CDMO项目的长期合作。 本次签署的《战略合作框架协议》仅为框架性协议，不涉及实质性交 易，不构成关联交易，也不构成《 ...

Core Viewpoint - Pro Pharmaceutical (000739.SZ) has announced a strategic partnership with Hangzhou Derui Zhiyao Technology Co., Ltd. to engage in long-term collaboration on CDMO projects, which will not involve substantial transactions or constitute related party transactions or major asset restructuring [1] Group 1 - The strategic cooperation framework agreement signed does not have a significant impact on the company's operating performance for the current year [1] - The future impact on the company's operating performance will depend on specific project agreements and implementation conditions [1]

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Hangzhou Derui Zhiyao Technology Co., Ltd. to establish a long-term partnership for CDMO projects, emphasizing mutual benefits and complementary advantages [1] Group 1 - The agreement is a framework agreement and does not involve substantial transactions [1] - The agreement does not constitute a related party transaction [1] - The agreement does not fall under the major asset restructuring regulations as per the listed company management measures [1] Group 2 - The signing of the strategic framework agreement does not require approval from the company's board of directors or shareholders [1]

Core Viewpoint - The article highlights the evolution and diversified business model of Hengdian Group, emphasizing its significant contributions to the film and tourism industry while also noting its substantial revenue from other sectors like electronics and pharmaceuticals [4][11]. Group 1: Company Overview - Hengdian Group has transformed from a local silk factory established in 1975 into a large conglomerate with total assets exceeding 100 billion yuan, spanning industries such as film and tourism, electronics, pharmaceuticals, and modern services [4][9][10]. - The founder, Xu Wenrong, and his son, Xu Yong'an, are described as low-profile billionaires, with the company’s wealth being attributed to collective efforts rather than individual ownership [11][12]. Group 2: Film and Tourism Industry - Hengdian has developed into the world's largest film shooting base, generating over 35 billion yuan annually from its film and tourism sectors, although this only accounts for less than 10% of the group's total revenue [4][5]. - The group offers free filming locations to attract film crews, resulting in a loss of approximately 20 million yuan annually, but this strategy has significantly boosted the local film industry and related services [5][6]. - In 2023 and 2024, Hengdian Film City is projected to receive 15.24 million and 13.93 million visitors, generating revenues of 2.638 billion yuan and 2.867 billion yuan, respectively [7]. Group 3: Financial Performance - Hengdian Group reported revenues of 94.2 billion yuan for the fiscal year 2024, with net profits reaching 3.124 billion yuan [9][10]. - Hengdian Film, the group's only publicly listed company, generated 1.971 billion yuan in revenue for 2024, with nearly 90% coming from cinema operations [7]. Group 4: Challenges and Adaptations - The company faces challenges such as declining market share in the magnetic materials sector and competition from short video formats in the film industry [14][15]. - Hengdian is adapting by investing in new projects, including a 12GW new energy battery project and expanding its airport facilities, with total investments in ongoing projects amounting to 11.678 billion yuan [14][15]. Group 5: Community Impact - The transformation of Hengdian from a small town with low income to a renowned "Oriental Hollywood" has significantly increased local residents' average annual income to 70,000 yuan [16].

Core Viewpoint - Pro Pharmaceutical (000739) plans to disclose its 2025 annual report on March 20, 2026, and encourages investors to pay attention to the announcement [1] Group 1 - The company will provide its annual report for the year 2025 on a specific date [1] - The announcement is aimed at keeping investors informed about the company's future disclosures [1]

Core Viewpoint - The company, Puluo Pharmaceutical Co., Ltd., has received a notice from its controlling shareholder, Hengdian Group Holdings Co., Ltd., regarding the increase in shareholding by its concerted action party, Dongyang Hengdian Yushan Sports Leisure Co., Ltd. This increase has brought the total shareholding of the controlling shareholder and its concerted action parties to 52.03% [2][4]. Group 1: Shareholding Changes - On January 13, 2026, Yushan Sports increased its shareholding by 1,653,500 shares, accounting for 0.14% of the company's total share capital, with a total investment of RMB 28,695,970 [2][4]. - Prior to this increase, Yushan Sports held 9,241,603 shares, representing 0.80% of the total share capital, while the total shareholding of the controlling shareholder and its concerted action parties was 51.89% [3][4]. Group 2: Future Shareholding Plans - Yushan Sports plans to increase its shareholding by an amount not less than RMB 60 million and not exceeding RMB 120 million within six months from January 13, 2026 [2][4]. - The increase will be executed through centralized bidding on the Shenzhen Stock Exchange, without a set price range, considering the intrinsic value of the stock and market trends [4][5]. Group 3: Funding and Commitments - The funds for the share purchase will come from Yushan Sports' own or raised funds [6]. - Yushan Sports has committed not to reduce its shareholding during the implementation period of the increase plan and will adhere to relevant regulations [6][10]. Group 4: Regulatory Compliance - The shareholding increase will not affect the company's compliance with listing conditions or change its control [8]. - Yushan Sports will maintain the increase amount unchanged in case of any corporate actions such as stock splits or dividends during the implementation period [9].

Group 1: Share Buybacks and Increases - Prolo Pharmaceutical's controlling shareholder plans to increase its stake by 60 million to 120 million yuan [3] - BAIC Blue Valley and some directors and executives plan to increase their holdings by 14.5 million to 16.4 million yuan [3] - Zhongju High-tech has obtained a commitment letter for a stock repurchase loan of 540 million yuan from a financial institution [3] - Haojiang Intelligent plans to use its own funds to repurchase shares for equity incentives or employee stock ownership plans [3] - Huazhi Jie intends to repurchase shares worth 30 million to 50 million yuan [3] - Nanshan Aluminum plans to repurchase shares worth 300 million to 600 million yuan for cancellation [3] Group 2: Share Reductions - New Work Group, a shareholder of Zhongxin Group, plans to reduce its stake by no more than 3% [3] - Hongqi Technology's shareholders plan to reduce their holdings by no more than 4.68% [3] - Zhejiang Yongqiang's shareholder, Xie Jianqiang, plans to reduce his stake by no more than 1.13% [3] - Xiangyu Medical's shareholder, Anyang Qixu, plans to reduce his stake by no more than 3% [3] - Shuyuan Pingmin's shareholder, Ali Health, plans to reduce his stake by no more than 2% [3] - Hongqiang Co., Ltd.'s actual controller plans to reduce no more than 2.1161 million shares, not exceeding 1% of the total share capital [3] - China Merchants Shipping's directors and executives plan to collectively reduce their holdings by no more than 648,600 shares [3] - Zhang Yijie, a shareholder of Jixin Technology, plans to reduce his stake by no more than 1% [3] - Dingjie Smart's major shareholder, Industrial Fulian, reduced its stake by 1.14% from January 9 to January 12 [3] - Zhongli Co., Ltd.'s shareholders plan to reduce their holdings by no more than 0.75% [3]

Group 1: Company Announcements - Hongsheng Co., Ltd. has not generated revenue in the data center liquid cooling sector [1][2] - Oriental Pearl does not directly engage in AI business, and AI applications do not directly generate revenue [1][2] - Tongda Hai's AI-driven revenue accounts for a low proportion of the company's overall operating income [2] Group 2: Project Investments - Beibu Gulf Port plans to invest 11.403 billion yuan in the construction of a 300,000-ton terminal project in Fangcheng Port [1][2] - LeKai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film coating production line project [2] Group 3: Contract Awards - Aopt has won a bid for a 120 million yuan 2D vision solution project for GoerTek in 2026 [1][2] - Anhui Expressway has won a project worth 7.237 billion yuan [2] Group 4: Equity Transfers - Aidi Pharmaceutical intends to acquire a 22.2324% stake in Nanda Pharmaceutical for 130 million yuan [1][2] Group 5: Share Buybacks - Kaifa Electric plans to repurchase shares worth between 30 million and 60 million yuan [1][2] - Haojiang Intelligent plans to repurchase shares worth between 1.5 million and 3 million yuan [3] - Huazhi Jie plans to invest 30 million to 50 million yuan in share repurchases [3] Group 6: Shareholding Changes - New Work Group, a shareholder of China New Group, plans to reduce its stake by no more than 3% [3] - Zhejiang Yongqiang's shareholder plans to reduce his stake by no more than 1.13% [3] - Xiangyu Medical's shareholder plans to reduce his stake by no more than 3% [3]